(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
Our research focuses on the biology of the eosinophil-lineage committed progenitor (EoP). We aim to identify novel therapeutic targets to regulate eosinophil production for the treatment of patients with inflammatory disorders by investigating transcriptional regulation of EoP generation and identifying and characterizing pathways important for EoP survival, proliferation and differentiation into mature eosinophils.
We have developed a number of innovative methods to study the regulation of eosinophil development including liquid culture systems in which we can follow differentiation of both murine and human eosinophil-lineage committed progenitors (EoPs) into mature effector eosinophils.
The pathways that we identify in our culture systems are tested in models of hypereosinophilia, infection and allergic inflammation to further characterize the clinical and therapeutic potential of candidate targets.
Eosinophil-associated disorders, including eosinophilic gastrointestinal disorders and asthma, are widely prevalent in developed and developing countries.
Current therapies can be effective, but resistance and toxic side effects often develop. New therapeutic agents are needed to treat patients with eosinophilic disorders.
Stem cell differentiation colony containing myeloid progenitors.
Fulkerson Lab Strategy Session
Learn more about how eosinophil progenitors contribute to asthma.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center